Midecamycin Acetate (CAS 55881-07-7) Suppliers and Product Information

Midecamycin Acetate is a semisynthetic diacetyl derivative of midecamycin A1. It is a macrolide antibiotic used for treating respiratory tract, dermatological, and surgical infections caused by gram-positive bacteria and mycoplasmas. It is generally less active than erythromycin, and some strains of H. influenzae and E. faecalis are resistant to it.

The drug is rapidly and extensively metabolized, with some metabolites retaining antibacterial activity. Absorption of the dry formulation is unaffected by food, while the oral suspension's absorption is delayed. Peak plasma concentrations vary based on dosage, ranging from 1.3-3 mg/L for doses between 400-800 mg.

Midecamycin Acetate is reported to have less toxicity compared to earlier macrolides. However, attention should be paid to its interaction with theophylline, which is similar to other macrolides.

Frequently Asked Questions

Q: What is the primary use of Midecamycin Acetate?

A: Midecamycin Acetate is primarily used as a broad-spectrum antibiotic for treating respiratory tract, dermatological, and surgical infections caused by gram-positive bacteria and mycoplasmas.

Q: How does Midecamycin Acetate compare to other antibiotics?

A: Midecamycin Acetate is generally less active than erythromycin. Some strains of H. influenzae and E. faecalis are resistant to it. However, it is reported to have less toxicity compared to earlier macrolides.

Q: Are there any significant drug interactions with Midecamycin Acetate?

A: Yes, attention should be paid to its interaction with theophylline, which is similar to interactions seen with other macrolide antibiotics.

Q: How is Midecamycin Acetate absorbed in the body?

A: The absorption of the dry formulation is unaffected by food, while the absorption of the oral suspension is delayed. The drug is rapidly and extensively metabolized, with some metabolites retaining antibacterial activity.